Brief: Akari Therapeutics Announces Shareholder Approval In Connection With Peak Bio Merger
08/11/2024 13:01
Nov 8 (Reuters) - Akari Therapeutics PLC AKTX.O :
* AKARI THERAPEUTICS ANNOUNCES SHAREHOLDER APPROVAL IN
CONNECTION
WITH PEAK BIO, INC. MERGER
* AKARI THERAPEUTICS PLC - MERGER TO RESULT IN 50% EQUITY
OWNERSHIP FOR AKARI AND PEAK BIO SHAREHOLDERS
Source text: ID:nGNX3pVZqj
Further company coverage: AKTX.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics